On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies. The reviews will continue while the company completes its pivotal Phase 3 trials in the U.K. and U.S. and through initial authorization for emergency use granted under country-specific regulations.